about
The future of transcatheter mitral valve interventions: competitive or complementary role of repair vs. replacement?Expanding Indications of Transcatheter Heart Valve InterventionsStandards of care: the EAPCI, guidelines and consensus documentsEarly exercise after coronary stenting is safeStent thrombosis is associated with an impaired response to antiplatelet therapyHeparin and coumadin versus acetylsalicylic acid for prevention of restenosis after coronary angioplastyEffect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosisCorrelation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosisTransient apical ballooning syndrome--clinical characteristics, ballooning pattern, and long-term follow-up in a Swiss populationQuality of care after acute coronary syndromes in a prospective cohort with reasons for non-prescription of recommended medicationsThe impact of renal impairment on long-term safety and effectiveness of drug-eluting stentsTechnical Approach Determines Inflammatory Response after Surgical and Transcatheter Aortic Valve ReplacementClinical outcome of high-risk patients with severe aortic stenosis and reduced left ventricular ejection fraction undergoing medical treatment or TAVIShort term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials.Long-term outcomes of patients receiving zotarolimus-eluting stents in ST elevation myocardial infarction, non-ST elevation acute coronary syndrome, and stable angina: data from the Resolute program.Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials.Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials.Predicting 3-year mortality after percutaneous coronary intervention: updated logistic clinical SYNTAX score based on patient-level data from 7 contemporary stent trials.Differences in coronary risk factors, procedural characteristics, mortality and stent thrombosis between two all-comers percutaneous coronary intervention registries from Europe and Japan: a patient-level data analysis of the Bern-Rotterdam and j-CyBioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data.Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study.Mid-term mechanical circulatory support: comparison of single-centre data with the EUROMACS registry.2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Associ[The role of percutaneus coronary interventions in the treatment of coronary artery disease].Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the PRISM Trial.Pitfalls in TAMVI: experience with the repositionable Lotus® Valve System.Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis.Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomizeTranscatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation.The self-expanding Symetis Acurate does not increase cerebral microembolic load when compared to the balloon-expandable Edwards Sapien prosthesis: a transcranial Doppler study in patients undergoing transapical aortic valve implantationFeasibility and outcomes of combined transcatheter aortic valve replacement with other structural heart interventions in a single session: a matched cohort study2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collabDynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months.2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment ElevatiStandardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research ConsortiumAssessing the cardiology community position on transradial intervention and the use of bivalirudin in patients with acute coronary syndrome undergoing invasive management: results of an EAPCI survey.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.SYNTAX score and Clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of SIRolimus-eluting stent compared with pacliTAXel-eluting stent for coronary revascularESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the
P50
Q26860834-05FCBB78-446F-4976-B9F4-ACAC4C7C1B94Q28079552-8B6B8303-0937-4CFB-B42B-1B650979BA0EQ28082950-8BFBBDB9-975B-4A45-B08B-3EF910AEA871Q28166024-7067FA63-E1E3-4778-B046-94420A1D2C32Q28176582-4A7757CE-240F-4AF8-8FBE-B82B6A0F883BQ28192448-3CC7216A-3812-4835-AAEA-C53BF28CD4BEQ28218481-6133B697-282C-479B-A781-1EE4AA4D950EQ28252547-EE0B2596-342C-41A5-B945-536ED4E45719Q28285996-4AB95792-1D09-48E1-902D-87B06606445FQ28541648-24CB8EB7-49C9-4F46-947E-908A38F4AF94Q28542739-C1948050-A5A5-4FA3-861D-1C8E1C1770FCQ28551135-2805F513-633D-433C-9368-3C309FB26363Q28742910-F5C1280E-68D9-4AF2-B5B8-7378DF62C729Q30241829-BD78E710-2D24-43FE-8B18-AE14CBE103A6Q30632676-DF4A6EAE-CAD5-452A-8AA3-987B531EEF5AQ30664323-B5EE1101-F525-4442-9C96-2B80614DBBAEQ30772369-EE7EA9BE-12D0-408C-AEAF-77246684642CQ30826000-850F6F20-6E6A-4E3F-B1CC-15B936554781Q30833868-5CC5B054-551D-4FE8-BA8E-A00A711A6465Q30859413-AFD53E93-4038-4340-B22F-5593C77655E8Q31102731-62F1868F-BDD7-4C47-9A80-D0450D77140BQ31139802-EB190C15-287E-4930-9C45-79DCB4DA5A3DQ33162947-81739996-AAAB-4851-A440-18E0B54FE2DAQ33428631-8A36C2DD-0945-408D-9C98-92D7DD1B07B6Q33434725-1931E565-F57A-455C-AB90-C606E1EB84FFQ33791596-9D4AC2D8-3A40-40D3-9EEB-A38AD86B5996Q33791885-A2B8A927-E57B-40F5-9B86-B1A614F06369Q34207990-7607E0DE-2797-4993-A367-ECB2D76AAF7CQ34271616-8065FBE6-C5B7-46A2-831E-C10D1B8CEF09Q34301540-8DAAAB6B-0D02-4FEE-B5D7-136CA2214766Q34333302-B6CE38A4-1273-40F3-BA47-4502C315A83BQ34351265-448C1C79-369C-493A-95CC-670C74C05462Q34368081-980C6917-5353-4B7C-B943-9837842FBB79Q34388921-A97AA460-420E-46CD-A15B-5ABEAADED8E8Q34491521-CE8ED55D-0335-40C7-919D-DE8BC3A228B6Q34492675-047E160A-0E4F-4365-8841-1377F102C17EQ34505340-B9FC7331-FE85-4AE8-83AA-58E3D45E22A9Q34538645-A1C203B3-CE6F-4877-9C90-D00651AE8CB5Q34632635-091228DF-2E36-4DE6-AD58-688FF665687BQ34640762-6EB05264-B776-4CAB-9DF0-EC9B3A5F2308
P50
description
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Stephan Windecker
@ast
Stephan Windecker
@en
Stephan Windecker
@es
Stephan Windecker
@nl
type
label
Stephan Windecker
@ast
Stephan Windecker
@en
Stephan Windecker
@es
Stephan Windecker
@nl
prefLabel
Stephan Windecker
@ast
Stephan Windecker
@en
Stephan Windecker
@es
Stephan Windecker
@nl
P106
P21
P214
35151897218724072737
P31
P496
0000-0003-2653-6762
P7859
lccn-n2019184923